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In the quest for markers of expression and progression for prostate cancer (PCa), the majority of studies have focussed on molecular
data exclusively from primary tumours. Although expression in metastases is inferred, a lack of correlation with secondary tumours
potentially limits their applicability diagnostically and therapeutically. Molecular targets were identified by examining expression
profiles of prostate cell lines using cDNA microarrays. Those genes identified were verified on PCa cell lines and tumour samples
from both primary and secondary tumours using real-time RT–PCR, western blotting and immunohistochemistry. Claudin-4, coding
for an integral membrane cell-junction protein, was the most significantly (Po0.00001) upregulated marker in both primary and
metastatic tumour specimens compared with benign prostatic hyperplasia at both RNA and protein levels. In primary tumours,
claudin-4 was more highly expressed in lower grade (Gleason 6) lesions than in higher grade (Gleason X7) cancers. Expression was
prominent throughout metastases from a variety of secondary sites in fresh-frozen and formalin-fixed specimens from both
androgen-intact and androgen-suppressed patients. As a result of its prominent expression in both primary and secondary PCas,
together with its established role as a receptor for Clostridium perfringens enterotoxin, claudin-4 may be useful as a potential marker
and therapeutic target for PCa metastases.
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The prostate-specific antigen (PSA) and transrectal ultrasound
biopsy approach for detection of prostate cancer (PCa) has
resulted in a stage shift in terms of earlier diagnosis (Hankey et al,
1999). However, even when the tumour is considered localised
clinically, a significant proportion of patients already have
micrometastases, which declare themselves subsequent to treat-
ment with curative intent (Freedland et al, 2003). Currently,
localised tumour is potentially curable but metastatic cancer is not
(Fusi et al, 2004). Intuitively, understanding key molecular events
leading to PCa will lead to the identification of potential diagnostic
and/or prognostic biomarkers, more reliable and earlier detection
together with implications for diagnostic and therapeutic targeting
(Hanahan and Weinberg, 2000). Methods used for the identifica-
tion of potential markers for PCa include gene expression analysis
(e.g. microarrays and quantitative PCR) and protein markers (e.g.
histopathology, mass spectrometry) (Ornstein and Tyson, 2006).
Numerous genes that are up- or downregulated in PCa have been
identified with a-methylacyl-CoA racemase (AMACR) (Rubin et al,
2002), prostate-specific membrane antigen (PSMA) (Burger et al,
2002), Hepsin (Stephan et al, 2004), DD3/PCA3 (Hessels et al, 2003)
and hTERT (Sommerfeld et al, 1996) among the more common
(Ross et al, 2003).
In PCa detection, greater value would be afforded if markers
were not only able to distinguish between benign and malignant
tumours, but also to indicate innate tumour aggressiveness
(including likelihood of metastasis). Their value would be
enhanced even further if expression in primary tumours correlated
with those in metastases and most valuable if they were also targets
for imaging and therapeutic strategies. Evidence to date indicates
that provision of such information is beyond the scope of any one
marker (Landers et al, 2005), and it is apparent that different genes
have relative strengths and weaknesses in this context. Thus, this
study aimed to correlate the use of potential biomarkers of PCa
primary lesions with metastases by comparing expression profiles
of normal prostate cells with those of clinically significant PCa cells
from primary and from metastatic tumours.
MATERIALS AND METHODS
Tissue culture
RWPE1 cells, derived from the peripheral zone of a histologically
normal adult human prostate and transformed with a single copy
of the human papilloma virus-18 (HPV-18), and metastatic PCa
cell lines ALVA41, DU145, LNCaP and PC3 were obtained from
Professor Judith Clements (Queensland University of Technology,
Australia). The PCa cell lines were cultured in 10% (v/v) FCS in
RPMI-1640 medium with 100Uml
 1 penicillin-G (GIBCOt
Invitrogen Corporation MT Waverley, Australia) and 100Uml
 1
streptomycin (GIBCO); RWPE1 cells were cultured in keratinocyte
serum-free media (KSFM; GIBCO) supplemented with 5ngml
 1
human recombinant epidermal growth factor and 0.05mgml
 1
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sbovine pituitary extract. Cell cultures were maintained at 371Ci na
humidified atmosphere of 5% CO2.
Specimen collection
All tissue specimens collected were obtained from consenting
patients Royal Brisbane Women’s Hospital, Queensland, as
approved by the Institutional Ethics Committee. Primary PCa
tissue specimens were obtained from patients undergoing either a
radical prostatectomy (RP) or a transurethral resection of prostate
(TURP) with secondary tumours provided by HS from both
androgen-intact and androgen-suppressed patients. Benign pro-
static hyperplasia (BPH) tissue specimens were obtained from men
who had either TURP or an open enucleative prostatectomy.
Tissue fragments were frozen immediately using liquid nitrogen
and transported on dry ice for storage at  701C with closely
adjacent tissue specimens placed in OCT and snap frozen or
formalin-fixed and paraffin-embedded. Tissues prepared for
histology were examined to confirm the diagnosis of BPH or
PCa and to determine the proportion of epithelial cells to stromal
cells. Nonsampled tissues were analysed histopathologically, as
per routine practice, to confirm the clinical diagnosis and, for
PCa, to determine Gleason scores and the percentage of tumour
cells present. Additional paraffin sections with high-grade
prostatic intraepithelial neoplasia (HG-PIN), PCa or metastatic
tissue were obtained by HS. Control benign sections, harvested
from deceased individuals following appropriate consent, were
kindly provided by Associate Professor David Horsfall (Hanson
Institute, Adelaide).
RNA extraction
Tissue fragments were homogenised using a Polytron PK
s
homogeniser, in 1ml TRI Reagent
s (Sigma-Aldrich, Castle Hill,
New South Wales, Australia) per 50mg of tissue. Prostate cell lines
were grown until confluent and 5–10 10
6 cells collected, washed
in PBS and resuspended in TRI Reagent and subsequently
extracted using the recommended protocol.
cDNA microarrays
Twenty micrograms of total RNA from a prostate cell line and
the reference RNA, isolated as described above, were indirectly
labelled with aminoallyl-dUTP (Amersham Biosciences,
Piscataway, NJ, USA) by reverse transcription using an oligo(dT)15
primer (Roche Diagnostics, Castle Hill, New South Wales,
Australia) and Superscript IIIt (Invitrogen). Following synthesis,
aminoallyl-labelled cDNA was purified, dried and the pellet
resuspended in 100mM sodium carbonate, pH 9.0. Cy5 or Cy3
dyes (Amersham Biosciences) were added to respective samples
and the coupling reaction allowed to proceed for 1h. Unincorpo-
rated dyes were removed from the reactions with 4 M hydro-
xylamine. The Cy3- and Cy5-labelled cDNAs were combined and
purified using QIAquickt PCR kit (Qiagen, Doncaster, Victoria,
Australia). Human Cot1 DNA (10mg) and polydA (2mg) were
added to the purified probe mix and dried before redissolving in
4  SSC, 50% deionised formamide and 0.25% SDS. Following
incubation at 951C for 5min and 451C for 90min, the labelled
probe mix was loaded on to a Human V6 custom microarray
prepared in house. Following hybridisation, the microarray chip
was washed in 0.2  SSC, 0.05% SDS, followed by 0.2  SSC and
centrifuged at low speed to dry. Cy3 and Cy5 fluorescence on the
microarray chip were detected with a GMS 418 Array Scanner
(Genetic Microsystems, Woburn, MA, USA) using Imagenet
(BioDiscovery, El Segundo, CA, USA). Data generated using Imagene
were normalised and filtered using the GeneSpringt (GeneWorks
Pty Ltd, The Barton, South Australia) software. Normalisations
included per spot and per chip intensity-dependent (Lowess)
normalisations; data transformation set measurements less than
0.01–0.01 and per chip normalisations to the 50th percentile. The
Human V6 microarray, consisting of 4600 cDNA probes B200bp in
length spotted in duplicate on a single chip, was developed in-house
and its use has been described by us previously (Burger et al, 2002).
Quantitative reverse transcription PCR
Primers for the candidate genes were designed using Taqman (PE
Applied Biosystems, Foster City, CA, USA) guidelines and
optimised using Amplitaq Gold. The following primers were
synthesised: b2-microglobulin forward 50-TGAATTCGTATGTGT
CTGGGT-30, b2-microglobulin reverse 50-CCTCCATGATGCTGCT
TACAT-30; claudin-4 forward 50-AGCTCTGTGGCCTCAGGACT
CT-30, claudin-4 reverse 50-CAGTGATGAATAGCTCTTCTTAAAT
TACAA-30; DAD1 forward 50-CAACCCACAGAACAAAGCGG-30,
DAD1 reverse 50-CTGCCATCTCCAGAACTCTTATCC-30; POX1
forward 50-GCTGGAAACCTGGCAGTGATAC-30, POX1 reverse
50-CAAAGGAAGAAAGGCTGGTCTCTC-30; TPD52 forward 50-GC
TGCTTTTTGCTCTGTTGGC-30 and TPD52 reverse 50-TTTTCT
GGAAGAGGCTCCGTGG-30. Real-time PCRs were performed in
15ml volumes (cDNA, 1  Plantinum
s SYBR Green Quantitative
PCR SuperMix-UDG (Life Technologiest) and 5pmol each
primer) using a 32-well Rotorgene real-time PCR machine (Corbett
Life Science, Mortlake, New South Wales, Australia). Cycles
consisted of a 941C, 2min hot start, 15s 941C denaturing step, a
15s 551C annealing step and a 15s 721C extension step for 35–40
cycles. The PCR finished with a melt curve between 55 and 1001C.
Expression of each gene was calculated using a standard curve
determined by expression of b2-microglobulin (b2M) in the control
normal prostate cell line, RWPE1. Prostate-specific antigen was
used to confirm that the RNA was of prostatic origin. Expression of
each gene was determined in an average of 18 BPH, 17 PCa and 5
metastatic lesions. The transcript value of each gene was normal-
ised in Excel by determining ratio of the candidate gene transcript/
b2M transcript value. Results are presented as mean±s.e.
Western blot analysis
Cells were washed and lysed in lysis buffer (20mM Tris pH 8.0,
1m M EDTA, 1mM (p-amidinophenyl) methanesulfonyl fluoride
hydrochloride and 1% (v/v) Triton X-100) as described by Liu et al
(1997). Protein concentration was estimated using the DC protein
Assay (Bio-Rad Laboratories Pty Ltd, Gladesville, New South Wales,
Australia) and BSA protein standards. The protein (20mg) samples
were mixed with loading buffer (2 : 0.5ml b-mercaptoethanol,
20% (v/v) glycerol, 2% (v/v) SDS, 37.3 M bromophenol blue, 0.25 M
Tris, pH 8.8) and heated to 1001C for 2min. Samples were resolved
on a 15% polyacrylamide gel (15% (v/v) acrylamide, 0.375 M Tris
pH 8.8, 0.1% (v/v) SDS, 0.1% (w/v) ammonium persulfate and 4ml
TEMED in 10ml) with stacking gel (1.5% (v/v) acrylamide, 0.038 M
Tris pH 6.8, 0.03% (v/v) SDS, 0.03% (w/v) ammonium persulfate
and 3ml TEMED) at 20mA in running buffer (25mM Tris, 0.19 M
Glycerine, 0.1% (v/v) SDS in H2O). Proteins were transferred onto
a nitrocellulose membrane in a carbonate buffer (10mM NaHCO3,
3m M Na2CO3, 20% (v/v) methanol in H2O) at 40V for 3h at
41C. Membranes were blocked in 5% (w/v) skim milk powder in
0.05% (v/v) Tween 20 in PBS (PBST) for 1h at RT and probed
overnight with anti-claudin-4 mouse antibody (3mg per 10ml in
PBST; Zymed
s Laboratories, San Francisco, CA, USA). Secondary
anti-mouse IgG antibody conjugated to horseradish peroxidase
(HRP) (Chemicon Australia Pty Ltd, Boronia, Victoria, Australia)
was added for 1h at 41C. Following washing with PBST, proteins
were detected using ECL Western blotting procedure (Amersham/
GE Healthcare Biosciences Pty Ltd, Rydalmere, New South Wales,
Australia) following the manufacturer’s instructions. b-actin was
also assayed to confirm protein loading was equal for all samples.
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sImmunofluorescent staining of claudin-4 in prostate cell
lines
ALVA41, DU145, LNCaP, PC3, RWPE1 and HeLa cells (1 10
4)
cultured in six-well plates were washed in 1% (v/v) FCS in PBS and
fixed in 4% paraformaldehyde for 30min at room temperature.
Cells were washed, permeabilised with 0.1% (v/v) Triton X-100 in
PBS for 30min, washed again and blocked in 5% skim milk in
PBST for 30min. After removal of blocking reagent, the fixed cells
were washed and incubated with the mouse anti-claudin-4
antibody (3mgml
 1) for 1h at RT. Cells were again washed and
incubated with the secondary anti-mouse IgG conjugated to FITC
for 20min. Cells were rinsed, stained with DAPI for 10min, washed
again and the coverslip inverted onto a slide with a drop of
80% (v/v) glycerol. The cells were visualised using a Carl Zeiss
fluorescence microscope (Axioskop 2 plus MOT).
Immunohistochemistry on paraffin-embedded sections
The paraffin-embedded prostate tissue sections were obtained from
patients with a range of prostate conditions, including 29 benign
prostate, 19 BPH, 19 PIN with no associated cancer, 25 PCa (including
21 with associated PIN) and 45 metastatic sections from a range of
distant sites. Paraffin-embedded prostate tissue sections were pro-
cessed as previously described (Burger et al, 2002). The paraffin tissue
sections were rehydrated in xylene for 5min and rinsed in 100%
e t h a n o lf o l l o w e db y7 0 %( v / v )e t h a n o la n dP B S .A n t i g e nr e t r i e v a l
within the sections was performed by covering the slides in citrate
buffer for 15min at 1051C and left to cool to room temperature. The
slides were incubated in 2% (v/v) hydrogen peroxidase for 15min to
inactivate endogenous peroxidases. Slides were washed in PBS and
blocked with 10% (v/v) goat serum and the primary antibody (anti-
claudin-4 raised in mouse, 3mgml
 1; anti-AMACR raised in mouse,
3mgml
 1; Zymed) overnight in a humidifier chamber. Control slides
were treated as above without the addition of the primary antibody.
The following day, sections were washed twice in PBS for 5min and
incubated with anti-mouse IgG HRP-conjugated secondary antibody
(DakoCytomation, EnVisionþ
s System: Dako Australasia Pty Ltd,
Kingsgrove, Australia) for 20min at room temperature. The labelled
secondary antibody was visualised by adding a substrate containing
diaminobenzadine (Zymed), and sections were counter-stained,
dehydrated and mounted.
RESULTS
Identification of metastatic markers for prostate cancer
We previously identified a number of genes upregulated in PCa,
which when used in combination represent useful biomarkers for
detection of this disease (Landers et al, 2005). As an extension of
this approach to relate these and additional markers of primary
PCa to PCa metastases, gene expression profiling was carried out
for three PCa metastatic tumour cell lines (ALVA41, DU145 and
LNCaP) and compared with the normal prostate cell line, RWPE1.
Reference RNA was also included by pooling total RNA from a
selection of different cell types. The cell lines were indirectly
labelled with Cy dyes and hybridised to an approximately 4600
gene in-house cDNA microarray chip. After an initial identification
of the genes upregulated in the pooled tumour lines compared with
the control cell line, RPWE1, these genes were plotted on a Venn
diagram that allowed for identification of a short list of 51 genes
upregulated twofold or greater, common to all three cell lines
(Figure 1). A list of these genes is presented in Table 1. Potential
biomarker candidate genes were selected not only on the basis of
fold change but also on the basis of a number of other criteria that
included twofold upregulation, published literature describing
expression in prostate, PCa or other cancers, function, potential as
a biomarker and whether the gene encoded a membrane protein
suitable for possible use in a diagnostic test. On the basis of these
criteria, we radically reduced the number of candidate genes to
four, claudin-4, defender against cell death 1 (DAD1), peroxi-
redoxin 1 (POX1) and tumour protein D52 (TPD52), which were
upregulated 3.7-, 2.1-, 3.3- and 3.2-fold, respectively (Table 1).
Confirmation of overexpression of these four genes was then
undertaken using real-time RT–PCR. When upregulation of
claudin-4, DAD1, POX1 and TPD52 was averaged across the three
PCa cell lines compared with RWPE1, values of 35-, 20-, 23- and
17-fold respectively, were observed (Figure 2), confirming data
from the cDNA microarray. Quantitative PCR was also employed
to compare the expression of these genes in BPH, primary tumours
and metastatic lesions. Claudin-4 was significantly (P¼0.00001)
upregulated by sixfold in PCa specimens (mean¼17.7) compared
with BPH (mean¼2.8; Figure 3 and Table 2). Similarly,
claudin-4 was significantly (P¼0.00001) upregulated by fivefold
in PCa metastases (mean¼14.2) compared with BPH. No
significant difference was observed between primary PCa and
PCa metastases. DAD1 was significantly (P¼0.005) upregulated
twofold in PCa (mean¼0.44) compared with BPH (mean¼0.18;
Figure 3 and Table 2). The sevenfold difference between PCa
metastases (mean¼1.26) and BPH was significant (P¼0.0001)
as well as the threefold difference between PCa and PCa metastases
(P¼0.003). POX1 was expressed significantly (P¼0.012) threefold
higher in PCa (mean¼0.96) compared with BPH (mean¼0.36)
and ninefold (P¼0.001) higher in BPH compared with PCa
metastases (mean¼3.4) and fourfold (P¼0.003) higher in
PCa metastasis compared with PCa (Figure 3; Table 2). TPD52
was significantly (P¼0.007) overexpressed in PCa (mean¼0.89)
compared with BPH (mean¼0.20) by fivefold. The seven-
fold difference between PCa metastases (mean¼1.41) and BPH
was significant (P¼0.008) but the twofold difference between
PCa and PCa metastases was not significant (P¼0.066). Although
the difference in transcript ratio between BPH and PCa was
significant for all four biomarkers, claudin-4 was selected for further
studies because of its high differential level of expression overall.
ALVA41 DU145
124
56
51
50
91
LNCaP
30
118
Figure 1 Venn diagram outlining genes upregulated in the metastatic
prostate tumour cell lines. Each circle represents genes expressed
approximately 4twofold in a metastatic tumour cell line (ALVA41,
DU145 and LNCaP) compared with the normal prostate cell line, RWPE1.
The number of genes upregulated in ALVA41 (red), DU145 (green) and
LNCaP (blue) was 124, 118 and 91, respectively. The overlapping regions
represent genes commonly overexpressed. Genes commonly upregulated in
all the three cell lines are represented in the centre white region (51 genes).
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cell lines
Immunoblotting was used to verify whether the increase in
claudin-4 transcript was also observed at the protein level.
Claudin-4 was present in all the metastatic prostate tumour cell
lines and decreased in the order of expression, PC3, DU145, LNCaP
and ALVA41 (Figure 4). Low levels of claudin-4 protein were also
detected in RWPE1, but, as expected, no protein was detected in
HeLa cells. The level of proliferating cell nuclear antigen (b-actin
B42kDa) served as a loading control (Figure 4).
Immunofluorescence was used to determine the localisation of
claudin-4 protein in the different cell lines (Figure 5A–F). The
nuclei of cells were stained with DAPI (Figure 5G–L) and the
images merged (Figure 5M–R). Claudin-4 staining was localised
predominantly in the cell membrane, with diffuse staining in the
cytoplasm of the metastatic prostate cell lines ALVA41, DU145,
LNCaP and PC3 (Figure 5M–P). Some membranous staining was
Table 1 Fifty-one genes upregulated in the metastatic prostate tumour cell lines, ALVA41, DU145 and LNCaP compared with the normal prostate cell
line, RWPE1
Gene ID Gene name RWPE1 ALVA41 DU145 LNCaP
Fold
change
AA280514 Thrombopoietin (myeloproliferative leukaemia) virus oncogene ligand, megakaryocyte
growth and development factor
0.1 0.8 2.0 0.3 10.4
AA461065 Thiosulphate sulphurtransferase (rhodanese) 0.1 0.8 1.9 0.3 8.9
AA464849 Thioredoxin reductase 0.1 1.0 2.0 0.3 8.8
AA488373 Phosphoglucomutase 1 0.5 7.2 2.2 3.3 8.1
N72215 Sulphated glycoprotein 1 0.2 1.0 1.8 0.6 5.8
AA431080 Keratin, type II cytoskeletal 6D 1.0 3.5 7.2 1.9 4.4
AA234982 Sarcoglycan, delta (35kDa dystrophin-associated) glycoprotein 0.3 1.4 1.2 1.5 4.2
AA495936 Glutathione S-transferase, microsomal 0.3 1.4 1.7 0.6 3.9
AA430665 hCPE-R CPE-receptor, complete cds 0.5 1.6 2.0 1.7 3.7
T95053 Rigui (RIGUI) mRNA, complete cds 0.4 2.0 1.1 1.5 3.7
Unknown unigene
42H1
Unknown unigene 42H1 0.2 0.8 0.7 0.7 3.7
AA894687 Nuclear factor NF45 mRNA, complete cds 0.3 1.1 0.9 0.8 3.5
AA490981 Prostate-specific antigen 0.7 2.0 1.4 3.7 3.5
AA063637 Palmitoyl protein thioesterase mRNA, complete cds 0.4 1.9 0.9 1.5 3.5
AA452933 Histone 2A-like protein (H2A/l) mRNA, complete cds 0.4 0.9 2.0 1.1 3.4
AA459100 19.8kDa protein mRNA, complete cds 0.3 1.0 0.9 0.9 3.3
T68892 Secreted frizzled related protein mRNA, complete cds 0.6 2.0 1.3 2.4 3.3
AA775803 Proliferation-associated gene A (natural killer-enhancing factor A) 0.3 1.4 0.9 0.9 3.2
AA459909 6-Pyruvoyl-tetrahydropterin synthase/dimerisation cofactor of hepatocyte nuclear
factor 1a (TCF1)
0.4 1.4 1.1 1.4 3.2
AA446839 E1B 19K/Bcl-2-binding protein Nip3 mRNA, nuclear gene encoding mitochondrial
protein, complete cds
0.3 0.6 0.9 1.3 3.2
AA454646 Lymphotoxin-b receptor precursor 0.5 1.5 1.5 1.6 3.1
R74169 Lymphocyte-specific protein LSP1 0.5 2.3 1.3 0.9 3.0
AA682613 p97 homologous protein, partial cds 0.7 2.1 2.6 1.8 3.0
Unknown unigene
42h1
Unknown unigene 42h1 0.3 0.9 0.8 0.7 3.0
AA410517 Cytoplasmic antiproteinase 0.5 1.1 1.9 1.0 2.9
H19203 Apo1_(MER5(Aop1-Mouse)-like protein), complete cds 0.2 0.4 0.6 0.7 2.8
H99676 Collagen, type VI, a 1 0.3 0.9 0.6 0.8 2.8
AA633882 Retinol dehydrogenase 1 (11-cis) 0.5 1.1 1.3 1.6 2.8
H99676 Collagen, type VI, a 1 0.3 0.9 0.6 0.8 2.8
AA034250 HES1 protein 0.4 1.2 0.8 1.1 2.7
AA402467 Transcription factor NFATx mRNA, complete cds 0.4 0.9 1.1 1.4 2.7
AA136054 ATP citrate lyase 0.4 0.8 1.1 0.8 2.6
AA459663 Antioxidant enzyme AOE37-2 mRNA, complete cds 0.3 0.7 0.6 1.1 2.6
AA873599 Iduronate 2-sulphatase (Hunter syndrome) 0.3 0.8 0.6 0.7 2.5
AA455126 ATP synthase lipid-binding protein P2 precursor 0.4 0.9 1.1 1.2 2.5
AA888182 Ribosomal protein S4, X-linked 0.3 0.8 0.6 0.9 2.4
W72140 Phosphofructokinase (liver type) 0.5 0.9 1.2 1.1 2.4
AA455281 Defender against cell death 1 0.4 1.0 0.9 0.8 2.3
R16195 HNK-1 sulphotransferase mRNA, complete cds 0.4 0.8 1.2 0.9 2.3
AA873577 ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit (oligomycin
sensitivity-conferring protein)
0.4 1.0 0.9 1.0 2.2
AA872402 Eukaryotic Initiation Factor 4B 0.5 1.2 0.8 1.1 2.2
AA459407 ATPase, DNA-binding protein (HIP116) mRNA, 30 end 0.5 1.1 1.0 1.0 2.2
AA491213 Splicing factor SRp30c mRNA, complete cds 0.4 1.0 0.9 0.8 2.2
AA234671 Peroxisomal membrane protein 1 (70kDa) Zellweger syndrome 0.4 0.7 1.1 0.8 2.2
AA872341 40S ribosomal protein S15A 0.4 0.8 0.7 1.1 2.1
N74956 RNA polymerase II polypeptide B (140kDa) 0.4 1.0 0.8 0.7 2.1
N33955 Protein phosphatase Wip1 mRNA, complete cds 0.9 1.8 1.7 1.8 2.0
R35231 SPOP 0.7 1.4 1.3 1.4 2.0
AA878561 Ubiquitin A-52 residue ribosomal protein fusion product 1 0.3 0.7 0.5 0.6 2.0
AA862813 Cytochrome c Oxidase Polypeptide VIII Precursor 0.5 1.1 1.0 1.1 2.0
AA479100 p76 mRNA, complete cds 0.3 0.6 0.6 0.6 2.0
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However, PC3 cells had a localised region of the membrane with
intense claudin-4 staining (Figure 5P). No claudin-4 staining was
evident in RWPE1 or the negative control HeLa cell line above
background (Figure 5Q–R).
Expression of claudin-4 in prostate tissue
As claudin-4 was expressed at variable amounts in the prostate cell
lines, it was important to determine whether upregulation and
overexpression were also present in PCa primary and secondary
tissues. Intensity of claudin-4 expression was classified as negative
( ), light (þ), moderate (þþ), strong (þþþ) or intense
positive (þþþþ). The percentage of cells stained were
categorised as either o 25, 25–50% or 450% of cells within the
section. In addition, staining was compared with that of PSMA and
AMACR (Jiang et al, 2001; Rubin et al, 2002). Immunohistochem-
ical analysis was undertaken on a range of prostatic sections
including, normal prostate, BPH, HG-PIN, PCa and metastases.
Benign epithelium in which claudin-4 and PSMA did stain
positively was localised to the cell membrane of luminal cells.
Membranous staining for claudin-4 and PSMA was also observed
in luminal cells of HG-PIN and in carcinoma cells. AMACR was
localised to the cytoplasm of luminal cells of benign epithelium or
HG-PIN and to the cytoplasm of carcinoma cells. Basal epithelium
and the surrounding stromal cells did not stain positively for
claudin-4, AMACR or PSMA. These findings are illustrated in
Figure 6. AMACR staining was localised to the cytoplasm of cells.
Claudin-4 staining was localised predominantly to the membrane
with weaker cytoplasmic staining, which seemed to be variable.
Similarly, PSMA was localised predominantly to the membrane.
Normal prostate sections
In the 29 normal prostate sections collected, claudin-4 was
localised to the cell membrane of luminal cells at a moderate
Table 2 Summary of real-time RT-PCR results
Claudin-4 DAD1 POX1 TPD52
Mean s.e. Mean s.e. Mean s.e. Mean s.e.
BPH 2.80 0.39 0.18 0.03 0.36 0.07 0.20 0.05
PCA 17.68 3.29 0.44 0.09 0.96 0.21 0.89 0.24
MET 14.21 1.14 1.26 0.51 3.39 0.46 1.41 0.93
Fold change P¼ Fold change P¼ Fold change P¼ Fold change P¼
BPH-PCA 6.3 0.00001 2.4 0.005 2.6 0.012 4.5 0.007
BPH-MET 5.1 0.00001 6.9 0.0001 9.3 0.001 7.1 0.008
PCA-MET 0.8 0.663 2.8 0.003 3.5 0.003 1.6 0.066
Abbreviations: BPH¼benign prostatic hyperplasia; PCa¼prostate cancer.
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Figure 2 Claudin-4, DAD1, POX1 and TPD52 expression in PCa cell
lines was assessed by quantitative real-time PCR. The transcript ratios
(candidate gene/transcripts of b2M) for each gene were plotted on a
logarithmic-scale graph (x axis). The candidate genes were examined in
duplicate within each PCR run, in at least two independent experiments.
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Figure 3 Claudin-4, DAD1, POX1 and TPD52 expression in BPH, PCa
and metastatic tissue samples was assessed using quantitative real-time
RT–PCR. The transcript ratios (candidate gene transcripts/b2M transcripts;
y axis) were plotted against patient samples (BPH, PCa and metastasis;
x axis). The expression of each candidate gene was determined in a
minimum of 18 BPH, 17 PCa and 5 metastatic tissue samples. Error bars
represent s.e. (standard error).
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Figure 4 Detection of claudin-4 in cell lines using western blot analysis.
Cell lysates from the metastatic prostate cell lines (ALVA41, DU145,
LNCaP and PC3), a normal prostate cell line (RWPE1) and a negative-
control cell line (HeLa) were run on a 15% SDS-PAGE under reducing
conditions and probed with an anti-claudin-4 antibody. High levels of
claudin-4 were visible in the prostate tumour cell lines with a low level
detected in RWPE1. No claudin-4 was detected in the negative control cell
line, HeLa. Detection of the proliferating cell nuclear antigen (PCNA)
served as a loading control.
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sintensity in 24% (7 out of 29), at a low intensity in 66% (19 out of
29) and was absent in 10% (3 out of 29) of the sections (Figure 6A;
Table 3). Approximately 25–50% of the cells stained positively in
most sections. There was no correlation with level of claudin-4
expression in the prostate and age. In the normal prostate sections,
AMACR staining was weak in 20% (3 out of 15) of sections and
absent in 80% (12 out of 15). Prostate-specific membrane antigen
was present at moderate levels of expression in 14% (2 out of 14),
at low levels in 79% (11 out of 14) and was absent in 7% (1 out
of 14) sections.
Benign prostatic hyperplasia
From 19 BPH sections, consisting of nodules of hyperplastic glands
and intervening stroma or stromal nodules (Foster, 2000), claudin-
4 staining was strong in 10.5% (2 out of 19) of cases and moderate
in 63.2% (12 out of 19) (Figure 6B; Table 2). The remaining
sections had either low (21%; 4 out of 19) or no (5.26%; 1 out of
19) claudin-4 staining. Staining was localised to the membrane and
in some cases to the cytoplasm of acinar cells. Weak AMACR
staining was detected in 14% (2 out of 14), and the remaining 86%
A      G                                   M
B     H          N 
C      I          O 
D      J          P 
E       K          Q 
F      L          R 
Figure 5 Immunofluorescent localisation of claudin-4 in cell lines. Claudin-4 localisation was examined in the adherent cell lines ALVA41 (A), DU145 (B),
LNCaP (C), PC3 (D), RWPE1 (E) and HeLa (F). Claudin-4 was detected with an anti-claudin-4 antibody and visualised with an anti-mouse IgG antibody
conjugated to FITC (A–F). Nuclei of cells were counterstained with DAPI (G–L). Images were merged (M–R) to determine correct localisation. The
metastatic prostate tumour cell lines ALVA41 (M), DU145 (N), LNCaP (O) and PC3 (P) revealed claudin-4 to be localised to the cell membrane between
cell-to-cell contact sites. The normal prostate cell line RPWE1 (Q) and the negative control cell line HeLa (R) did not reveal any claudin-4 localisation.
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s(12 out of 14) did not reveal any staining. Prostate-specific
membrane antigen was expressed moderately in 31% (4 out of 13)
and weakly in 54% (7 out of 13; Figure 6: Table 3). The remaining
sections (15%; 2 out of 13) did not have any PSMA present.
High-grade prostatic intraepithelial neoplasia
Both focal and extensive HG-PIN, characterised by progressive
basal layer disruption, loss of markers of secretory differentiation,
nuclear and nucleolar abnormalities, increasing proliferative
potential, microvessel density, variation in DNA content and
allelic loss (Bostwick et al, 2004), were studied. Initially, 18
sections with HG-PIN without invasive carcinoma were examined
for claudin-4 expression. From the 18 HG-PIN sections obtained,
72% (13 out of 18) were of a moderate intensity for claudin-4
expression (Figure 6C; Table 3). Within these sections, 450% of
the cells were positive for claudin-4, with staining localised to the
membrane of HG-PIN cells. The remaining 11% (2 out of 18) of
sections were strong or 17% (3 out of 18) low. AMACR staining
was high in 9% (1 out of 11), moderate in 9% (1 out of 11), low in
36% (4 out of 11) and absent in 46% (5 out of 11) of HG-PIN in the
absence of invasive carcinoma. Prostate-specific membrane anti-
gen was present at a high level in 9% (1 out of 11), at a low level in
55% (6 out of 11) and absent in 36% (4 out of 11) of sections.
A 
B
C
D 
E
F
H&E AMACR Claudin-4 PSMA
Figure 6 Immunohistochemical staining of AMACR, claudin-4 and PSMA representative of that observed in a range of prostate conditions. Adjacent
sections were stained with haematoxylin and eosin (H and E), AMACR, claudin-4 and PSMA for each prostate tissue examined. Tissue sections consist
of a normal (A), BPH (B), HG-PIN without invasive carcinoma (C), HG-PIN with invasive carcinoma (D and E) and metastatic carcinoma (lymph node; F).
(A and B) Arrows indicate benign glands; (C) arrow indicates HG-PIN; (D) black arrow indicates HG-PIN and red arrow indicates PCa (Gleason 3þ4);
(E) black arrow indicates benign epithelial cells and red arrow indicates PCa (Gleason 5þ5); (F) arrow indicates cancerous cells present at a
metastatic site.
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As PCa is commonly associated with the presence of HG-PIN
(Bostwick et al, 2000), PCa sections were collected from 25
individuals, with 21 of the sections containing HG-PIN and PCa.
Strong staining for claudin-4 was present (71%; 15 out of 21), with
moderate staining in 28.5% (6 out of 21) or 425% of cells
(Figure 6D; Table 3). On the other hand, the majority of the
invasive tumour cells studied exhibited moderate staining (64%; 16
out of 25) for claudin-4, whereas 24% (6 out of 25) were strong and
8% (2 out of 25) low. Interestingly, lower grade (Gleason grade 3)
tumours had higher staining for claudin-4 compared with higher
grade (Gleason grade 5) tumours (Figure 6E; Table 3). Further-
more, benign glands in the PCa sections were moderate (56%;
14 out of 25) to high (44%; 11 out of 25) for claudin-4 staining and,
in some cases, higher than that found in invasive carcinoma cells.
High-grade prostatic intraepithelial neoplasia cells found within
PCa sections demonstrated low (32%; 6 out of 19) to moderate
(21%; 4 out of 19) levels of expression for AMACR, with a small
percentage staining high (10%; 2 out of 19). The remaining 37%
(7 out of 19) did not have AMACR present. In invasive carcinoma
cells, AMACR staining was intense in 5% (1 out of 21), high in 33%
(7 out of 21), moderate in 24% (5 out of 21), low in 24% (5 out of
21) and absent in 14% (3 out of 21) of cases. Benign epithelial cells
in those sections showed low staining for AMACR (5%; 1 out of
21), whereas the remaining (95%; 20 out of 21) sections did not
show AMACR. Prostate-specific membrane antigen staining of
HG-PIN cells in the presence of invasive carcinoma was high in
Table 3 Immunohistochemical evaluation of AMACR, PSMA and claudin-4 expression in prostate tissue sections
Percentage and intensity of cells staining
o25% 25–50% 450% o25% 25–50% 450% o25% 25–50% 450%
Normal prostate sections AMACR (n¼15) PSMA (n¼14) Claudin-4 (n¼29)
Nil 12 1 3
Low 3 3 6 2 3 12 4
Moderate 1 1 5 2
Strong
Intense
BPH AMACR (n¼14) PSMA (n¼13) Claudin-4 (n¼19)
Nil 12 2 1
Low 1 1 1 2 4 1 3
Moderate 1 2 1 1 6 5
Strong 2
Intense
HG-PIN (with no foci of PCa) AMACR (n¼11) PSMA (n¼11) Claudin-4 (n¼18)
Nil 5 4
Low 3 1 6 1 2
Moderate 1 11 2
Strong 1 1 1 1
Intense
PCa AMACR (n¼21) PSMA (n¼21) Claudin-4 (n¼25)
Nil 3
Low 3 2 1 2 2 1 1
Moderate 1 2 2 3 5 3 9 4
Strong 1 6 1 1 6 3 2 1
Intense 1 1
HG-PIN (with foci of PCa) AMACR (n¼19) PSMA (n¼18) Claudin-4 (n¼21)
Nil 7
Low 4 2 4 2 1
Moderate 2 2 3 5 2 4
Strong 1 1 3 1 8 6
Intense
Benign glands (adjacent to PCa) AMACR (n¼21) PSMA (n¼21) Claudin-4 (n¼25)
Nil 20 3
Low 1 5 3 3
Moderate 2 4 1 7 7
Strong 26 3
Intense
Metastatic sites AMACR (n¼18) PSMA (n¼16) Claudin-4 (n¼45)
Nil 11 3
Low 5 4 1 3 1 9
Moderate 6 2 3 1 4 2 6 5
Strong 6 4 2 1 3 13
Intense 13
Abbreviations: AMACR¼a-methylacyl-CoA racemase; BPH¼benign prostatic hyperplasia; HG-PIN¼high-grade prostatic intraepithelial neoplasia; PCa¼prostate cancer;
PSMA¼prostate-specific membrane antigen. Immunohistochemical staining for AMACR, PSMA and claudin-4 was performed on a number (n) of prostate sections. The
percentage and the intensity of cells staining within each of the sections were determined by a uropathologist.
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s17% (3 out of 18) of sections, moderate in 44% (8 out of 18) and
low in 39% (7 out of 18). In contrast, PSMA was high in 38% (8 out
of 21) of sections containing invasive carcinoma cells, moderate in
38% (8 out of 21) and low in 24% (5 out of 21). The benign cells in
these sections were high for PSMA in 33% (7 out of 21) of PCa
sections and low in 52% (11 out of 21) of sections. The remaining
14% (3 out of 21) of sections did not have any PSMA present
(Table 3).
PCa metastatic lesions
Although lymph node and bone metastases predominate in
patients with advanced PCa (Bubendorf et al, 2000), lesions from
a wide range of secondary sites were studied (45 sections in total).
Specimens from both androgen-intact and androgen-suppressed
patients were isolated from a range of tissues including lymph
nodes (18 out of 45), bone (8 out of 45), liver (1 out of 45), lung
(1 out of 45), penile (2 out of 45), seminal vesicles (2 out of 45) and
biopsies of pelvic retroperitoneal tumours (13 out of 45). From the
45 tumour metastases sections examined, 36% (16 out of 45) had
strong, 29% (13 out of 45) had moderate, 20% (9 out of 45) had low
and 7% (3 out of 45) had negative staining for claudin-4. It was
also observed that a small percentage (9%; 4 out of 45) of
metastases showed intense staining for claudin-4. Furthermore, in
47% of sections of metastases, 450–100% of carcinoma cells
stained positively for claudin-4 (Figure 6F; Table 3). Those sections
with intense claudin-4 staining included liver, lymph node, bone
and lung metastases. AMACR expression was high in 16% (6 out of
38) of sections and moderate in 92% (11 out of 38). Twenty-six per
cent (10 out of 38) of the sections had low staining for AMACR,
whereas the remaining (29%; 11 out of 38) of sections had no
AMACR staining. Prostate-specific membrane antigen staining of
sections with metastases revealed high levels in 44% (7 out of 16),
moderate levels in 31% (5 out of 16) and low levels in 25% (4 out of
16) of sections (Table 3).
DISCUSSION
In previous work, we examined the expression profiles of prostatic
tissues using cDNA microarrays, which revealed d-Catenin and
PSMA to be significantly overexpressed in primary PCa tumours
compared with BPH (Burger et al, 2002). In addition, we revealed
that a combination of four PCa biomarkers, UDP-N-acetyl-a-D-
galactosamine transferase (GalNAc-T3), PSMA, Hepsin and DD3/
PCA3 represented a powerful new approach for detecting all
PCa cells by molecular profiling (Landers et al, 2005). The present
study was designed to extend this approach to encompass
metastases in addition to primary PCa. Fifty-one genes were
upregulated in all three of the metastatic cell lines and of these
claudin-4, DAD1, POX1 and TPD52 were selected for detailed
evaluation. From the four candidate genes, our findings indicated
that claudin-4 had the greatest potential as a PCa biomarker for
both primary tumours and metastases.
Claudins are essential components of tight junction structures
(Morita et al, 1999) and show a distinct organ-specific distribution
in the body (Rahner et al, 2001). Claudin-4 encodes a 209 amino-
acid (22kDa) protein that contains four putative transmembrane
regions (Katahira et al, 1997a) sharing close homology with
claudin-3. Both claudin-4 and claudin-3 (to a lesser extent)
function as receptors for Clostridium perfringens enterotoxin
(CPE) (Katahira et al, 1997b), the virulence factor responsible for
the symptoms of C. perfringens strain A food poisoning. By
targeting intestinal epithelial cells, CPE is thought to act by
forming small pores to increase membrane permeability with a
subsequent loss of osmotic equilibrium resulting in cell lysis (Stark
and Duncan, 1971; Matsuda and Sugimoto, 1979).
There have been previous reports to indicate that claudin-4 is
upregulated in primary breast (Kominsky et al, 2004; Tokes et al,
2005), ovarian (Rangel et al, 2003; Agarwal et al, 2005; Santin et al,
2005), prostate (Long et al, 2001; Sheehan et al, 2007) squamous
cell carcinoma (Morita et al, 2004) and pancreatic cancers
(Michl et al, 2001, 2003; Nichols et al, 2004; Sato et al, 2004) but
is downregulated in gastric cancer (Lee et al, 2005). In this study,
the increasing prominence of claudin-4 compared with other
candidate genes evaluated at both RNA and protein levels was
confirmed with highest levels in PCa metastatic cells. Long et al
(2001) observed claudin-4 expression in metastatic prostate tissue
samples; however, they failed to observe expression in the
metastatic cell lines LNCaP and PC3, attributing this inconsistency
to the possibility of alterations induced with long periods of
passaging (Long et al, 2001). Interestingly, we found that claudin-4
localisation in PC3 cells was confined to only a sector of the
membrane but the reasons for this finding are unclear. One
possible explanation is a loss of cellular organisation due to a
defect in tight junction formation or cell polarity, features
common in tumour cells (Weinstein et al, 1976).
Immunohistochemical staining in situ confirmed localisation of
claudin-4 and PSMA to the membrane of luminal cells of benign
epithelial glands and HG-PIN as well as PCa cells (Chang et al,
1999), with increasing expression for claudin-4 from benign,
through premaligant to malignant, being most evident in
metastatic PCas. In the few cases in which AMACR was present
in benign glands or HG-PIN, it was localised to the cytoplasm of
luminal cells (Hameed and Humphrey, 2005) with a similar
localisation in PCa cells. Normal prostate sections exhibited a low
level of staining for claudin-4 and PSMA, but the majority was
negative for AMACR. Benign prostatic hyperplasia glands stained
primarily with a moderate intensity for claudin-4 compared with
PSMA and AMACR, which stained at low intensity and negatively,
respectively.
High-grade prostatic intraepithelial neoplasia, previously consi-
dered to be an invariable precursor lesion of PCa and commonly
found in association with PCa, does not always proceed to invasive
carcinoma and, when it does, this may develop decades later
(Montironi et al, 2002). In considering this relationship, sections
containing HG-PIN without associated invasive carcinoma were of
moderate intensity for claudin-4 and of low intensity for PSMA
and AMACR. Cells containing HG-PIN in association with invasive
carcinoma exhibited strong levels of claudin-4 staining. In
contrast, AMACR levels were low and PSMA levels moderate. This
observation that claudin-4 expression is increased in HG-PIN in
the presence of PCa may indicate that claudin-4 plays a role in the
early events of PCa development.
Although a moderate level of staining for claudin-4 was evident
in the majority of invasive PCa cells, a closer examination of
tumour sections revealed that claudin-4 expression tended to be
higher in lower grade carcinomas compared with those of higher
grades (Gleason 5) (data not shown). Furthermore, epithelial cells
in surrounding benign glands within the PCa sections also had
moderate to strong claudin-4 staining. As cellular organisation is
lost in cancer, not uncommonly a reduction in tight junction
function is observable, consistent with changes in cellular polarity
associated with increased cellular mobility (Weinstein et al, 1976).
Prostate cancer metastases examined by immunohistochemistry
were from a range of secondary sites. Most of the metastatic
tumours stained positively for claudin-4, with the majority
classified as strong or intense and only a minority registering
moderate expression. No difference was evident in specimens from
androgen-suppressed and nonandrogen-suppressed patients (data
not shown). Furthermore, there did not appear to be a correlation
with type of metastatic site and the intensity of claudin-4
expression: those sections with the strongest claudin-4 staining
were from liver, lymph node, bone and lung. Although decreased
polarity and differentiation are regarded as important for the
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smetastatic phenotype, to enable individual cells to leave the
primary site and enter the circulation to reach distant sites (Martin
and Jiang, 2001), circumstances are different in established
metastases in which a reversal is required to permit growth of
established secondary lesions (Yang et al, 2006).
Sheehan et al (2007) in their evaluation of 141 RP specimens
reported an increase in claudin-4 expression in advanced-stage
tumours compared with adjacent benign glands and concluded
that claudin-4 expression persisted in PCa and correlated with an
adverse prognosis. In contrast, our study of both primary and
secondary lesions examined 182 sections from patients with a
range of prostate conditions to provide a better understanding of
the role of claudin-4 in the prostate and in tumour progression:
our findings are consistent with current concepts of the
carcinogenesis/invasion process. A further difference to the report
from Sheehan et al (2007) is that our immunohistochemical
analysis of claudin-4 was supported by a comparative evaluation of
AMACR and PSMA, two well-established PCa markers.
In a small study of pancreatic cancer, Michl et al (2003)
concluded that claudin-4 expression tended to be stronger in well-
differentiated tumours compared with poorly differentiated
tumours, which correlates with the expression pattern observed
within PCa primary lesions in this study. Also, in primary
pancreatic cancer sections, Nichols et al (2004) reported that
immunohistochemical expression of claudin-4 was present in
pancreatic intraepithelial neoplasia cells and in all of the metastatic
cancers examined (Nichols et al, 2004) reflecting our observation
that claudin-4 expression was present in all HG-PIN sections
associated with PCa.
It is not known what regulates claudin-4 expression; however,
studies in pancreatic cancer have implicated the TGF-b pathway
(Michl et al, 2003). TGF-b is known as a potent mediator of
tumour progression by inducing cell spreading, migration,
angiogenesis and tumour cell invasion (Wikstrom et al, 1998;
Massague et al, 2000). A study into the regulation of claudin-4 by
TGF-b revealed that this cytokine downregulated claudin-4
expression within pancreatic cancer, which may be the mechanism
by which TGF-b promotes tumour invasion (Michl et al, 2003).
Furthermore, inhibition of Ras signalling by dominant-negative
Ras and specific inhibitors of downstream effectors, mitogen-
activated protein/extracellular signal-regulated kinase kinase and
phosphatidylinositol 30-kinase, has been suggested to decrease
claudin-4 expression (Michl et al, 2003). More recently, over-
expression of claudin-4 in ovarian cancer was found to be partly
regulated by a small region in the claudin-4 promoter-containing
Sp1 sites (Honda et al, 2006). The claudin-4 promoter is also
controlled by epigenetic modifications (Boireau et al, 2007). It was
revealed that cells overexpressing claudin-4 exhibited low DNA
methylation and high histone H3 acetylation of the critical claudin-
4 promoter region with the converse observed for cells expressing
low levels of claudin-4 (Boireau et al, 2007). Studies are currently
underway in our laboratory to determine if this mechanism is also
responsible for the regulation of claudin-4 in the prostate.
The results obtained within this study have revealed a distinct
and progressing pattern of claudin-4 expression within the
prostate with noncancerous pathological changes as well as in
PCa and PCa metastases by RT–PCR and immunohistochemistry
of both primary and secondary tumours. In addition, elevated
levels of claudin-4 were observed in suspected premalignant and
malignant lesions.
Many genes and proteins have been proposed as useful markers
for diagnosis, imaging and therapeutic targeting in PCa. In
diagnosis, the large proportion of those nominated was related
to an aggressive phenotype with relatively few identified as
potential indicators of low risk PCa. With burgeoning numbers
of this category of patients being identified as a consequence of
PSA screening, there is a pressing need for low-risk disease
markers, particularly for those men considering close observation
(Smith and Catalona, 1994; Hoedemaeker et al, 2000). However,
before claudin-4 can be considered for any role in this regard
despite its proclivity to be overexpressed preferentially in lower
Gleason score tumours, further evaluation is essential. Similarly,
its potential as a target for imaging or therapy must remain
speculative until further definitive research is undertaken.
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